ProQR Therapeutics (NASDAQ:PRQR) Downgraded by StockNews.com to “Hold”

ProQR Therapeutics (NASDAQ:PRQRGet Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

PRQR has been the topic of several other research reports. Chardan Capital raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Wednesday, November 8th. Raymond James cut their price objective on shares of ProQR Therapeutics from $5.00 to $4.00 and set an “outperform” rating on the stock in a report on Wednesday, November 8th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $3.72.

Read Our Latest Research Report on ProQR Therapeutics

ProQR Therapeutics Stock Down 4.5 %

NASDAQ:PRQR traded down $0.10 during mid-day trading on Wednesday, hitting $2.00. The stock had a trading volume of 169,170 shares, compared to its average volume of 370,394. The stock has a 50-day simple moving average of $2.07 and a two-hundred day simple moving average of $1.71. The company has a market capitalization of $161.64 million, a PE ratio of -4.26 and a beta of 0.20. ProQR Therapeutics has a twelve month low of $1.11 and a twelve month high of $3.85. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 0.06.

Hedge Funds Weigh In On ProQR Therapeutics

A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at $69,000. BNP Paribas Financial Markets increased its holdings in shares of ProQR Therapeutics by 137.3% in the 4th quarter. BNP Paribas Financial Markets now owns 15,901 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 9,200 shares during the period. GSA Capital Partners LLP increased its holdings in shares of ProQR Therapeutics by 69.0% in the 3rd quarter. GSA Capital Partners LLP now owns 74,084 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 30,248 shares during the period. Monaco Asset Management SAM increased its holdings in shares of ProQR Therapeutics by 58.9% in the 3rd quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company’s stock valued at $491,000 after acquiring an additional 140,000 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in ProQR Therapeutics in the 2nd quarter valued at $325,000. 26.15% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

(Get Free Report)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

Further Reading

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.